Novo Nordisk’s diabetes pill slashes risk of cardiovascular complications by 14% after four years – CNBC

by

  1. Novo Nordisk’s diabetes pill slashes risk of cardiovascular complications by 14% after four years CNBC
  2. Semaglutide, or Ozempic, reduces symptoms of feared diabetes’ complication, study finds The Globe and Mail
  3. Ozempic® (semaglutide) injection 1 mg showed improved functional outcomes and health-related quality of life in Phase 3 STRIDE trial in adults with type 2 diabetes and peripheral artery disease (PAD) presented at ACC 2025 Yahoo Finance
  4. STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients TCTMD
  5. SOUL: Oral Semaglutide Cuts MACE by 14% in People with Type 2 Diabetes MD Magazine

Read original article here

Leave a Comment